A Scalable Manufacturing Approach to Single Dose Vaccination against HPV
1
Department of NanoEngineering, University of California San Diego, La Jolla, CA 92093, USA
2
Center for Nano-ImmunoEngineering, University of California San Diego, La Jolla, CA 92093, USA
3
Institute for Materials Discovery and Design, University of California San Diego, La Jolla, CA 92093, USA
4
Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA
5
Department of Radiology, University of California San Diego, La Jolla, CA 92093, USA
6
Moores Cancer Center, University of California-San Diego, La Jolla, CA 92093, USA
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally as first authors to this work.
Vaccines 2021, 9(1), 66; https://doi.org/10.3390/vaccines9010066
Received: 12 December 2020 / Revised: 11 January 2021 / Accepted: 15 January 2021 / Published: 19 January 2021
(This article belongs to the Special Issue Plant Based Vaccines- A Powerhouse for Global Health)
Human papillomavirus (HPV) is a globally prevalent sexually-transmitted pathogen, responsible for most cases of cervical cancer. HPV vaccination rates remain suboptimal, partly due to the need for multiple doses, leading to a lack of compliance and incomplete protection. To address the drawbacks of current HPV vaccines, we used a scalable manufacturing process to prepare implantable polymer–protein blends for single-administration with sustained delivery. Peptide epitopes from HPV16 capsid protein L2 were conjugated to the virus-like particles derived from bacteriophage Qβ, to enhance their immunogenicity. The HPV-Qβ particles were then encapsulated into poly(lactic-co-glycolic acid) (PLGA) implants, using a benchtop melt-processing system. The implants facilitated the slow and sustained release of HPV-Qβ particles without the loss of nanoparticle integrity, during high temperature melt processing. Mice vaccinated with the implants generated IgG titers comparable to the traditional soluble injections and achieved protection in a pseudovirus neutralization assay. HPV-Qβ implants offer a new vaccination platform; because the melt-processing is so versatile, the technology offers the opportunity for massive upscale into any geometric form factor. Notably, microneedle patches would allow for self-administration in the absence of a healthcare professional, within the developing world. The Qβ technology is highly adaptable, allowing the production of vaccine candidates and their delivery devices for multiple strains or types of viruses.
View Full-Text
Keywords:
HPV vaccine candidate; L2 protein; Qβ; virus-like particles (VLPs); PLGA implants; vaccine delivery device; hot melt extrusion
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 2002 KiB)
MDPI and ACS Style
Shao, S.; Ortega-Rivera, O.A.; Ray, S.; Pokorski, J.K.; Steinmetz, N.F. A Scalable Manufacturing Approach to Single Dose Vaccination against HPV. Vaccines 2021, 9, 66. https://doi.org/10.3390/vaccines9010066
AMA Style
Shao S, Ortega-Rivera OA, Ray S, Pokorski JK, Steinmetz NF. A Scalable Manufacturing Approach to Single Dose Vaccination against HPV. Vaccines. 2021; 9(1):66. https://doi.org/10.3390/vaccines9010066
Chicago/Turabian StyleShao, Shuai; Ortega-Rivera, Oscar A.; Ray, Sayoni; Pokorski, Jonathan K.; Steinmetz, Nicole F. 2021. "A Scalable Manufacturing Approach to Single Dose Vaccination against HPV" Vaccines 9, no. 1: 66. https://doi.org/10.3390/vaccines9010066
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit
